The Role of Digital Therapeutics and Artificial Intelligence in Chronic Disease Management: A Narrative Review

Abstract

We conducted research showing that chronic disease management continued to challenge healthcare systems, payers, and patients. At the same time, digital therapeutics emerged as a promising and potentially transformative approach. They supported better management of long-term conditions, improved patient outcomes, and helped streamline healthcare delivery. We carried out a comprehensive literature search to identify both original reports and reviewed publications. The search covered multiple databases, including Google Scholar and PubMed, and we also gathered relevant information from credible online sources such as the World Health Organization and India’s National Crime Records Bureau. Using these findings, the narrative explained how digital therapeutics reshaped chronic disease management by highlighting key benefits, the technologies that enabled these solutions, and the expected impacts on both clinical and economic outcomes. We also discussed the obstacles the sector encountered as it developed, and we considered the future prospects of digital therapeutics in chronic care. In conclusion, digital therapeutics offered personalised care, improved patient engagement and adherence, provided real-time monitoring and feedback, enhanced accessibility and convenience, and were cost-effective in managing chronic disease; however, challenges such as cybersecurity concerns, reliability of data, the digital divide, and a lack of extensive clinical validation needed to be addressed for widespread adoption. While the evidence to date suggested clear clinical and economic promise, realizing that promise required coordinated action stronger clinical trials to build robust evidence, clear regulatory pathways to ensure safety and efficacy, investment in secure interoperable infrastructure, and targeted efforts to close the digital divide so vulnerable populations were not left behind; policymakers, clinicians, payers, and technology developers had to collaborate to translate innovation into equitable, scalable care improvements.